7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A physician-reviewed guide to zoledronic acid's FDA approval history, current compounding legal status, label requirements, and post-market safety data. Updated with primary-source citations.
A physician-reviewed comparison of how the FDA and EMA regulate zoledronic acid (Reclast/Aclasta), covering approved indications, label differences, post-market safety requirements, and what each approach means for patients.
A clinical review of zoledronic acid (Reclast) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including osteonecrosis of the jaw, atypical femoral fractures, renal toxicity, and atrial fibrillation.
Complete FDA approval timeline for zoledronic acid (Reclast/Zometa), including original indications, label expansions, safety communications, and post-market surveillance findings.
Complete regulatory overview of zoledronic acid (Reclast/Aclasta) covering FDA approval history, EMA authorization, labeled indications, boxed warnings, and global post-market surveillance data.
A detailed review of every FDA label update to Reclast (zoledronic acid) from 2020 through 2026, including boxed warnings, new contraindications, dosing guidance, and post-market safety signals, reviewed by the HealthRX.com medical team.
A clinical overview of zoledronic acid's regulatory history, current label, post-market safety data, and the next-generation bone agents in development that may eventually succeed it.